Cipla to acquire 21 pc stake in Achira Labs for Rs 25 cr

The investment will facilitate a Cipla entity's strategic participation in the PoC diagnostics and AMR (antimicrobial resistance) space through the design, development, and manufacturing of microfluidics-based technologies Pharma major Cipla Ltd on Friday said it will acquire 21.05 per cent stake for Rs 25 crore in Achira Labs Pvt Ltd, which is engaged in development and commercialisation of point of care (PoC) medical test kits in India. The company has signed definitive agreements with Achira Labs for the purpose, Cipla said in a regulatory filing. "This investment will facilitate a Cipla entity's strategic participation in the PoC diagnostics and AMR (antimicrobial resistance) space through the design, Cipla CEO, One India Business, Achin Gupta said, "This investment will further our commitment of bringing innovative, affordable and quality diagnostic solutions for all. We are guided by our purpose of Caring for Life and will continue to make strategic investments to ensure access to point of care test kit solutions." A PoC that enables rapid identification of the bug causing an infection would be extremely helpful in choosing the appropriate antibiotic early in the treatment process. Cipa said the transaction is expected to be completed within 60 days from "the signing of definitive agreements or such other date mutually agreed between the parties and will be subject to conditions precedent set out in the definitive agreements." Bengaluru-based Achira is a medical diagnostics company and develops medical diagnostic products using microfluidic technology with an aim to bring sophisticated medical tests closer to the point of diagnosis, treatment and management.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!